https://pt.psychopharmacologyinstitute.com/section/a-psicofarmacologia-da-agitacao-gerenciando-emergencias-comportamentais/ 2026-09-01T17:16:54+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-da-agitacao-avaliacao-medica-escalas-de-classificacao-e-diagnostico-diferencial/ 2026-09-01T17:16:58+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnosticos-psiquiatricos-em-pacientes-agitados-delirium-demencia-e-transtornos-psicoticos/ 2026-09-01T17:17:02+00:00 https://pt.psychopharmacologyinstitute.com/section/outros-diagnosticos-psiquiatricos-em-pacientes-agitados-transtornos-de-humor-e-de-uso-de-substancias-2/ 2026-09-01T17:17:07+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-nao-farmacologicas-para-controlar-a-agitacao-reducao-da-escalada-verbal/ 2026-09-01T17:17:11+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-farmacologicas-para-o-controle-da-agitacao-recomendacoes-gerais-e-metas-de-tratamento/ 2026-09-01T17:17:16+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-dos-antipsicoticos-no-controle-da-agitacao/ 2026-09-01T17:17:20+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-dos-benzodiazepinicos-e-da-dexmedetomidina-no-controle-da-agitacao/ 2026-09-01T17:17:24+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-uma-abordagem-alternativa-para-pacientes-agitados/ 2026-09-01T17:17:28+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-12/ 2026-09-01T17:17:32+00:00 https://pt.psychopharmacologyinstitute.com/section/algoritmo-de-psicofarmacologia-do-tept-introducao-e-visao-geral-pt/ 2026-09-01T17:17:41+00:00 https://pt.psychopharmacologyinstitute.com/section/ptsd-em-situacoes-especiais-uso-de-substancias-transtorno-bipolar-psicose-e-gestacao-pt/ 2026-09-01T17:17:44+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-das-perturbacoes-do-sono-no-tept-pesadelos-despertares-e-terrores-noturnos-pt/ 2026-09-01T17:17:48+00:00 https://pt.psychopharmacologyinstitute.com/section/prazosina-para-pesadelos-no-tept-protocolos-de-dosagem-para-homens-e-mulheres-pt/ 2026-09-01T17:17:52+00:00 https://pt.psychopharmacologyinstitute.com/section/iniciacao-do-sono-no-tept-hidroxizina-trazodona-e-clonidina-pt/ 2026-09-01T17:17:57+00:00 https://pt.psychopharmacologyinstitute.com/section/quetiapina-benzodiazepinicos-e-triciclicos-por-que-evita-los-para-o-sono-no-tept-pt/ 2026-09-01T17:18:02+00:00 https://pt.psychopharmacologyinstitute.com/section/selecao-de-um-ssri-para-tept-sertralina-paroxetina-e-escitalopram-pt/ 2026-09-01T17:18:06+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-para-ptsd-com-sintomas-psicoticos-risperidona-aripiprazol-e-quetiapina-pt/ 2026-09-01T17:18:10+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-segunda-linha-para-tept-venlafaxina-duloxetina-e-mirtazapina-pt/ 2026-09-01T17:18:15+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-terceira-linha-para-ptsd-prazosina-diurna-e-clonidina-para-hiperexcitabilidade-pt/ 2026-09-01T17:18:19+00:00 https://pt.psychopharmacologyinstitute.com/section/tept-resistente-ao-tratamento-topiramato-antipsicoticos-e-opcoes-de-augmentacao-pt/ 2026-09-01T17:18:23+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-10912-pt/ 2026-09-01T17:18:27+00:00 https://pt.psychopharmacologyinstitute.com/section/tendencias-no-uso-de-medicamentos-psicotropicos-em-adultos-idosos-pt/ 2026-09-01T17:18:36+00:00 https://pt.psychopharmacologyinstitute.com/section/alteracoes-farmacologicas-relacionadas-a-idade-consideracoes-para-idosos-pt/ 2026-09-01T17:18:40+00:00 https://pt.psychopharmacologyinstitute.com/section/desafios-na-prescricao-de-psicofarmacos-na-populacao-geriatrica-pt/ 2026-09-01T17:18:44+00:00 https://pt.psychopharmacologyinstitute.com/section/consideracoes-sobre-ssri-e-snri-em-idosos-posologia-efeitos-adversos-e-monitorizacao-pt/ 2026-09-01T17:18:48+00:00 https://pt.psychopharmacologyinstitute.com/section/prescricao-de-mirtazapina-bupropiona-tcas-e-maois-na-populacao-geriatrica-pt/ 2026-09-01T17:18:52+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-de-potencializacao-e-ect-na-depressao-geriatrica-pt/ 2026-09-01T17:18:57+00:00 https://pt.psychopharmacologyinstitute.com/section/estabilizadores-do-humor-em-idosos-litio-acido-valproico-e-agentes-alternativos-pt/ 2026-09-01T17:19:01+00:00 https://pt.psychopharmacologyinstitute.com/section/prescricao-de-antipsicoticos-em-idosos-consideracoes-clinicas-pt/ 2026-09-01T17:19:05+00:00 https://pt.psychopharmacologyinstitute.com/section/benzodiazepinicos-e-bras-em-idosos-consideracoes-clinicas-pt/ 2026-09-01T17:19:09+00:00 https://pt.psychopharmacologyinstitute.com/section/farmacoterapia-da-demencia-dos-inibidores-da-colinesterase-as-terapias-anti-amiloide-pt/ 2026-09-01T17:19:12+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9611-pt/ 2026-09-01T17:19:17+00:00 https://pt.psychopharmacologyinstitute.com/section/introducao-a-clozapina-indicacoes-e-efeitos-adversos-comuns/ 2026-09-01T17:19:25+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-da-clozapina-para-psicose-resistente-ao-tratamento-e-transtornos-de-humor-2/ 2026-09-01T17:19:29+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-da-clozapina-para-risco-de-suicidio-e-agressao/ 2026-09-01T17:19:33+00:00 https://pt.psychopharmacologyinstitute.com/section/indicacoes-de-uso-off-label-da-clozapina/ 2026-09-01T17:19:37+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-do-pre-tratamento-e-consentimento-para-o-uso-da-clozapina/ 2026-09-01T17:19:41+00:00 https://pt.psychopharmacologyinstitute.com/section/inicio-e-otimizacao-da-clozapina/ 2026-09-01T17:19:45+00:00 https://pt.psychopharmacologyinstitute.com/section/monitoramento-da-clozapina-sistema-rems/ 2026-09-01T17:19:49+00:00 https://pt.psychopharmacologyinstitute.com/section/controle-da-febre-e-dos-efeitos-adversos-hematologicos-da-clozapina-2/ 2026-09-01T17:19:53+00:00 https://pt.psychopharmacologyinstitute.com/section/gerenciamento-dos-efeitos-adversos-cardiacos-e-metabolicos-da-clozapina/ 2026-09-01T17:19:57+00:00 https://pt.psychopharmacologyinstitute.com/section/controle-de-outros-efeitos-adversos-comuns-da-clozapina/ 2026-09-01T17:20:01+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-controle-dos-efeitos-colaterais-durante-a-titulacao-da-clozapina/ 2026-09-01T17:20:06+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-5/ 2026-09-01T17:20:10+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-tendencias-emergentes-da-mortalidade-materna/ 2026-09-01T17:20:18+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-diagnostico-diferencial-das-sindromes-de-humor-pos-parto/ 2026-09-01T17:20:22+00:00 https://pt.psychopharmacologyinstitute.com/section/diferenciando-o-blues-pos-parto-da-depressao-pos-parto/ 2026-09-01T17:20:26+00:00 https://pt.psychopharmacologyinstitute.com/section/psicose-pos-parto-identificando-e-avaliando-uma-emergencia-psiquiatrica/ 2026-09-01T17:20:31+00:00 https://pt.psychopharmacologyinstitute.com/section/distinguir-o-toc-pos-parto-da-psicose-pos-parto/ 2026-09-01T17:20:36+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-reconhecendo-e-gerenciando-a-depressao-pos-parto/ 2026-09-01T17:20:41+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-depressao-pos-parto-estrategias-nao-farmacologicas/ 2026-09-01T17:20:45+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-pos-parto-consideracoes-farmacologicas-para-maes-que-amamentam-2/ 2026-09-01T17:20:49+00:00 https://pt.psychopharmacologyinstitute.com/section/emt-e-ect-tratamentos-eficazes-para-transtornos-de-humor-pos-parto/ 2026-09-01T17:20:53+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-da-brexanolona-e-da-zuranolona-na-depressao-pos-parto/ 2026-09-01T17:20:57+00:00 https://pt.psychopharmacologyinstitute.com/section/psicose-pos-parto-estrategias-farmacologicas/ 2026-09-01T17:21:01+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-2-4/ 2026-09-01T17:21:06+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-a-resposta-psicologica-ao-cancer/ 2026-09-01T17:21:14+00:00 https://pt.psychopharmacologyinstitute.com/section/transtornos-depressivos-e-risco-de-suicidio-em-pacientes-com-cancer/ 2026-09-01T17:21:18+00:00 https://pt.psychopharmacologyinstitute.com/section/fazendo-o-diagnostico-correto-depressao-versus-tristeza-e-desmoralizacao/ 2026-09-01T17:21:23+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-transtornos-depressivos-em-pacientes-com-cancer/ 2026-09-01T17:21:28+00:00 https://pt.psychopharmacologyinstitute.com/section/transtornos-de-ansiedade-em-pacientes-com-cancer/ 2026-09-01T17:21:32+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-transtornos-de-ansiedade-em-pacientes-com-cancer/ 2026-09-01T17:21:36+00:00 https://pt.psychopharmacologyinstitute.com/section/delirium-uma-complicacao-neuropsiquiatrica-em-pacientes-com-cancer/ 2026-09-01T17:21:41+00:00 https://pt.psychopharmacologyinstitute.com/section/delirium-em-pacientes-com-cancer-diagnostico-e-implicacoes-2/ 2026-09-01T17:21:45+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-do-delirium-em-pacientes-com-cancer-2/ 2026-09-01T17:21:49+00:00 https://pt.psychopharmacologyinstitute.com/section/gerenciamento-do-delirium-em-pacientes-com-cancer/ 2026-09-01T17:21:52+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-4/ 2026-09-01T17:21:56+00:00 https://pt.psychopharmacologyinstitute.com/section/tendencias-atuais-no-uso-de-antidepressivos-e-diretrizes-de-descontinuacao-pt/ 2026-09-01T17:22:05+00:00 https://pt.psychopharmacologyinstitute.com/section/mecanismos-neurobiologicos-da-sindrome-de-descontinuacao-de-antidepressivos-pt/ 2026-09-01T17:22:09+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-da-sindrome-de-descontinuacao-de-antidepressivos-distincao-em-relacao-a-recaida-pt/ 2026-09-01T17:22:13+00:00 https://pt.psychopharmacologyinstitute.com/section/desprescricao-de-antidepressivos-racional-clinico-e-barreiras-frequentes-pt/ 2026-09-01T17:22:18+00:00 https://pt.psychopharmacologyinstitute.com/section/reducao-hiperbolica-de-antidepressivos-base-neurobiologica-pt/ 2026-09-01T17:22:22+00:00 https://pt.psychopharmacologyinstitute.com/section/reducao-hiperbolica-de-antidepressivos-evidencias-clinicas-pt/ 2026-09-01T17:22:26+00:00 https://pt.psychopharmacologyinstitute.com/section/implementacao-da-reducao-hiperbolica-de-antidepressivos-opcoes-de-formulacao-e-consideracoes-clinicas-pt/ 2026-09-01T17:22:31+00:00 https://pt.psychopharmacologyinstitute.com/section/desprescricao-de-ssris-e-mirtazapina-tecnicas-de-reducao-hiperbolica-pt/ 2026-09-01T17:22:35+00:00 https://pt.psychopharmacologyinstitute.com/section/desprescricao-de-snris-tecnicas-de-reducao-hiperbolica-pt/ 2026-09-01T17:22:40+00:00 https://pt.psychopharmacologyinstitute.com/section/casos-clinicos-pt/ 2026-09-01T17:22:44+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9811-pt/ 2026-09-01T17:22:48+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-de-entrevista-motivacional-para-usuarios-de-benzodiazepinicos-2/ 2026-09-01T17:22:55+00:00 https://pt.psychopharmacologyinstitute.com/section/desprescricao-de-benzodiazepinicos-indicacoes-beneficios-e-riscos/ 2026-09-01T17:22:58+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-dos-principios-da-reducao-gradual-do-uso-de-benzodiazepinicos/ 2026-09-01T17:23:03+00:00 https://pt.psychopharmacologyinstitute.com/section/tecnicas-para-uma-reducao-bem-sucedida-do-uso-de-benzodiazepinicos/ 2026-09-01T17:23:07+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-e-controle-dos-sintomas-de-abstinencia-de-benzodiazepinicos/ 2026-09-01T17:23:11+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-complexidades-da-disfuncao-neurologica-induzida-por-benzodiazepinicos-bind/ 2026-09-01T17:23:15+00:00 https://pt.psychopharmacologyinstitute.com/section/alem-da-interrupcao-do-uso-de-benzodiazepinicos-compreensao-dos-efeitos-na-vida-e-estrategias-de-apoio/ 2026-09-01T17:23:19+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-14/ 2026-09-01T17:23:22+00:00 https://pt.psychopharmacologyinstitute.com/section/subtipos-do-transtorno-bipolar-apresentacoes-classicas-vs-atipicas-pt/ 2026-09-01T17:23:31+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-da-depressao-bipolar-exames-laboratoriais-graficos-de-humor-e-escalas-de-temperamento-pt/ 2026-09-01T17:23:36+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-bipolar-mista-caracteristicas-clinicas-e-estrategias-de-tratamento-pt/ 2026-09-01T17:23:40+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-bipolar-tipo-inflamatorio-pt/ 2026-09-01T17:23:44+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-bipolar-tipo-vascular-pt/ 2026-09-01T17:23:48+00:00 https://pt.psychopharmacologyinstitute.com/section/litio-para-depressao-bipolar-pt/ 2026-09-01T17:23:52+00:00 https://pt.psychopharmacologyinstitute.com/section/lamotrigina-para-depressao-bipolar-pt/ 2026-09-01T17:23:56+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-de-segunda-geracao-para-depressao-bipolar-pt/ 2026-09-01T17:24:00+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-adjuvantes-para-depressao-bipolar-pramipexol-t3-e-fototerapia-pt/ 2026-09-01T17:24:04+00:00 https://pt.psychopharmacologyinstitute.com/section/modafinil-omega-3-e-outras-opcoes-de-terceira-linha-para-depressao-bipolar-pt/ 2026-09-01T17:24:08+00:00 https://pt.psychopharmacologyinstitute.com/section/cetamina-tms-e-ect-para-depressao-bipolar-pt/ 2026-09-01T17:24:13+00:00 https://pt.psychopharmacologyinstitute.com/section/pontos-principais-pt/ 2026-09-01T17:24:17+00:00 https://pt.psychopharmacologyinstitute.com/section/definindo-a-insonia-diagnostico-e-fisiopatologia-pt/ 2026-09-01T17:24:25+00:00 https://pt.psychopharmacologyinstitute.com/section/epidemiologia-e-rastreamento-da-insonia-pt/ 2026-09-01T17:24:29+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-de-primeira-linha-para-insonia-foco-na-tcc-i-pt/ 2026-09-01T17:24:33+00:00 https://pt.psychopharmacologyinstitute.com/section/antagonistas-duais-dos-receptores-de-orexina-eficacia-posologia-e-seguranca-pt/ 2026-09-01T17:24:38+00:00 https://pt.psychopharmacologyinstitute.com/section/z-drugs-e-benzodiazepinicos-para-insonia-pt/ 2026-09-01T17:24:42+00:00 https://pt.psychopharmacologyinstitute.com/section/agonistas-melatoninergicos-posologia-qualidade-e-eficacia-da-melatonina-e-do-ramelteon-pt/ 2026-09-01T17:24:46+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-para-insonia-doxepina-trazodona-e-mirtazapina-pt/ 2026-09-01T17:24:50+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-anti-histaminicos-e-magnesio-para-insonia-pt/ 2026-09-01T17:24:54+00:00 https://pt.psychopharmacologyinstitute.com/section/insonia-na-gravidez-e-em-idosos-escolhendo-o-agente-mais-seguro-pt/ 2026-09-01T17:24:58+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-eszopiclona-para-insonia-perimenopausal-pt/ 2026-09-01T17:25:02+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-10811-pt/ 2026-09-01T17:25:06+00:00 https://pt.psychopharmacologyinstitute.com/section/farmacoterapia-para-o-transtorno-por-uso-de-alcool-evidencias-eficacia-e-lacunas-no-tratamento-pt/ 2026-09-01T17:25:16+00:00 https://pt.psychopharmacologyinstitute.com/section/naltrexona-para-o-transtorno-por-uso-de-alcool-posologia-monitorizacao-e-seguranca-hepatica-pt/ 2026-09-01T17:25:20+00:00 https://pt.psychopharmacologyinstitute.com/section/acamprosato-no-transtorno-por-uso-de-alcool-mecanismo-de-acao-posologia-eficacia-e-seguranca-pt/ 2026-09-01T17:25:24+00:00 https://pt.psychopharmacologyinstitute.com/section/dissulfiram-no-transtorno-por-uso-de-alcool-mecanismos-eficacia-e-consideracoes-sobre-seguranca-hepatica-pt/ 2026-09-01T17:25:27+00:00 https://pt.psychopharmacologyinstitute.com/section/gabapentina-topiramato-e-baclofeno-no-transtorno-por-uso-de-alcool-pt/ 2026-09-01T17:25:31+00:00 https://pt.psychopharmacologyinstitute.com/section/algoritmo-para-o-transtorno-por-uso-de-alcool-selecao-de-medicamentos-com-base-no-status-hepatico-pt/ 2026-09-01T17:25:35+00:00 https://pt.psychopharmacologyinstitute.com/section/tua-com-comorbidades-respiratorias-e-infecciosas-ajustes-farmacologicos-pt/ 2026-09-01T17:25:39+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-do-tau-em-pacientes-com-doenca-cardiovascular-e-renal-concomitante-pt/ 2026-09-01T17:25:43+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-pt/ 2026-09-01T17:25:47+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9210-pt/ 2026-09-01T17:25:50+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-dos-transtornos-alimentares-visao-geral-e-caso-clinico-pt/ 2026-09-01T17:25:58+00:00 https://pt.psychopharmacologyinstitute.com/section/bulimia-nervosa-medicamentos-que-funcionam-pt/ 2026-09-01T17:26:02+00:00 https://pt.psychopharmacologyinstitute.com/section/consideracoes-fundamentais-na-prescricao-para-bulimia-nervosa-pt/ 2026-09-01T17:26:05+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-da-farmacoterapia-na-anorexia-nervosa-pt/ 2026-09-01T17:26:08+00:00 https://pt.psychopharmacologyinstitute.com/section/anorexia-com-sintomas-do-humor-uma-abordagem-farmacologica-direcionada-pt/ 2026-09-01T17:26:12+00:00 https://pt.psychopharmacologyinstitute.com/section/farmacoterapia-do-transtorno-da-compulsao-alimentar-periodica-antidepressivos-e-anticonvulsivantes-pt/ 2026-09-01T17:26:17+00:00 https://pt.psychopharmacologyinstitute.com/section/farmacoterapia-do-transtorno-da-compulsao-alimentar-lisdexanfetamina-pt/ 2026-09-01T17:26:20+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-decisoes-terapeuticas-na-bulimia-nervosa-pt/ 2026-09-01T17:26:24+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-8109-pt/ 2026-09-01T17:26:28+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-indicacoes-e-os-usos-off-label-da-lamotrigina/ 2026-09-01T17:26:35+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-dos-mecanismos-da-lamotrigina-e-do-cronograma-de-titulacao/ 2026-09-01T17:26:39+00:00 https://pt.psychopharmacologyinstitute.com/section/lamotrigina-efeitos-colaterais-e-consideracoes-especiais/ 2026-09-01T17:26:43+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-os-possiveis-efeitos-colaterais-cardiacos-da-lamotrigina-e-da-ms-um-caso/ 2026-09-01T17:26:47+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-da-lamotrigina-no-prolongamento-do-qtc-e-no-alargamento-do-qrs/ 2026-09-01T17:26:51+00:00 https://pt.psychopharmacologyinstitute.com/section/outras-complicacoes-cardiacas-associadas-ao-uso-da-lamotrigina/ 2026-09-01T17:26:55+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-para-uso-seguro-e-monitoramento-adequado-da-lamotrigina/ 2026-09-01T17:26:59+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-abordagem-pratica-no-caso-do-ms-a-s-case/ 2026-09-01T17:27:03+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-13/ 2026-09-01T17:27:06+00:00 https://pt.psychopharmacologyinstitute.com/section/introducao-e-como-persuadir-os-pacientes-a-tomar-litio-pt/ 2026-09-01T17:27:14+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-basal-monitorizacao-e-dosagem-ideal-do-litio-pt/ 2026-09-01T17:27:18+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-dos-efeitos-colaterais-renais-da-litioterapia-pt/ 2026-09-01T17:27:23+00:00 https://pt.psychopharmacologyinstitute.com/section/como-mitigar-o-ganho-de-peso-e-os-efeitos-colaterais-gastrointestinais-do-litio-pt/ 2026-09-01T17:27:27+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-da-disfuncao-tireoidiana-e-paratireoidiana-com-litio-pt/ 2026-09-01T17:27:31+00:00 https://pt.psychopharmacologyinstitute.com/section/abordagem-do-comprometimento-cognitivo-e-tremor-associados-ao-litio-pt/ 2026-09-01T17:27:35+00:00 https://pt.psychopharmacologyinstitute.com/section/abordagem-da-disfuncao-sexual-alopecia-e-erupcoes-cutaneas-associadas-ao-litio-pt/ 2026-09-01T17:27:39+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-litio-no-manejo-de-um-paciente-complexo-com-transtorno-bipolar-pt/ 2026-09-01T17:27:42+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-8709-pt/ 2026-09-01T17:27:46+00:00 https://pt.psychopharmacologyinstitute.com/section/aprendendo-os-conceitos-basicos-do-sono/ 2026-09-01T17:27:53+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-a-relacao-entre-o-transtorno-de-insonia-e-o-tdm/ 2026-09-01T17:27:57+00:00 https://pt.psychopharmacologyinstitute.com/section/abordagens-diagnosticas-e-estrategias-de-avaliacao-para-insonia-2/ 2026-09-01T17:28:01+00:00 https://pt.psychopharmacologyinstitute.com/section/intervencoes-nao-farmacologicas-para-insonia/ 2026-09-01T17:28:05+00:00 https://pt.psychopharmacologyinstitute.com/section/intervencoes-farmacologicas-para-insonia-benzodiazepinicos-e-hipnoticos-nao-benzodiazepinicos/ 2026-09-01T17:28:09+00:00 https://pt.psychopharmacologyinstitute.com/section/outras-intervencoes-farmacologicas-para-insonia-2/ 2026-09-01T17:28:13+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-de-tratamento-para-controlar-a-insonia-no-tdm-2/ 2026-09-01T17:28:17+00:00 https://pt.psychopharmacologyinstitute.com/section/papel-dos-tratamentos-com-cetamina-e-neuroestimulacao-na-insonia-comorbida-com-tdm/ 2026-09-01T17:28:21+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-sr-b/ 2026-09-01T17:28:24+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-9/ 2026-09-01T17:28:28+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-a-catatonia-terminologia-e-subtipos-pt/ 2026-09-01T17:28:36+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-de-catatonia-dicas-de-avaliacao-pt/ 2026-09-01T17:28:39+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-de-catatonia-o-teste-desafio-com-lorazepam-pt/ 2026-09-01T17:28:43+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-diferencial-e-identificacao-das-causas-subjacentes-da-catatonia-pt/ 2026-09-01T17:28:46+00:00 https://pt.psychopharmacologyinstitute.com/section/complicacoes-medicas-e-consideracoes-prognosticas-na-catatonia-pt/ 2026-09-01T17:28:50+00:00 https://pt.psychopharmacologyinstitute.com/section/farmacoterapia-da-catatonia-o-papel-dos-benzodiazepinicos-pt/ 2026-09-01T17:28:54+00:00 https://pt.psychopharmacologyinstitute.com/section/terapias-de-neuromodulacao-ect-e-rtms-na-catatonia-pt/ 2026-09-01T17:28:58+00:00 https://pt.psychopharmacologyinstitute.com/section/antagonistas-do-nmda-no-manejo-da-catatonia-amantadina-memantina-e-cetamina-pt/ 2026-09-01T17:29:02+00:00 https://pt.psychopharmacologyinstitute.com/section/outras-estrategias-farmacologicas-para-a-catatonia-zolpidem-bromocriptina-e-cariprazina-pt/ 2026-09-01T17:29:06+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-9410-pt/ 2026-09-01T17:29:10+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9411-pt/ 2026-09-01T17:29:14+00:00 https://pt.psychopharmacologyinstitute.com/section/funcionamento-sexual-perspectivas-biopsicossociais-e-neurobiologicas-pt/ 2026-09-01T17:29:20+00:00 https://pt.psychopharmacologyinstitute.com/section/disfuncao-sexual-como-sintoma-efeito-adverso-e-fator-de-risco-para-depressao-pt/ 2026-09-01T17:29:24+00:00 https://pt.psychopharmacologyinstitute.com/section/condicoes-medicas-e-medicamentos-nao-psiquiatricos-que-afetam-a-funcao-sexual-pt/ 2026-09-01T17:29:27+00:00 https://pt.psychopharmacologyinstitute.com/section/disfuncao-sexual-induzida-por-antidepressivos-mecanismos-genetica-e-prevalencia-pt/ 2026-09-01T17:29:31+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-com-baixo-risco-de-disfuncao-sexual-evidencias-de-ensaios-clinicos-pt/ 2026-09-01T17:29:35+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-colaterais-sexuais-de-antipsicoticos-estabilizadores-do-humor-e-benzodiazepinicos-pt/ 2026-09-01T17:29:38+00:00 https://pt.psychopharmacologyinstitute.com/section/comunicacao-sobre-a-funcao-sexual-um-imperativo-clinico-pt/ 2026-09-01T17:29:42+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-da-disfuncao-sexual-induzida-por-sri-substituicao-antidotos-e-fatores-modificaveis-pt/ 2026-09-01T17:29:46+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-contraceptivos-orais-como-causa-negligenciada-de-disfuncao-sexual-pt/ 2026-09-01T17:29:49+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9910-pt/ 2026-09-01T17:29:53+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-colaterais-dos-antipsicoticos-visao-geral-dos-perfis-de-receptores-pt/ 2026-09-01T17:30:00+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-da-sedacao-induzida-por-antipsicoticos-pt/ 2026-09-01T17:30:03+00:00 https://pt.psychopharmacologyinstitute.com/section/ganho-de-peso-induzido-por-antipsicoticos-prevencao-e-manejo-pt/ 2026-09-01T17:30:07+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-terapeuticas-para-acatisia-e-parkinsonismo-pt/ 2026-09-01T17:30:11+00:00 https://pt.psychopharmacologyinstitute.com/section/reconhecimento-e-manejo-da-sindrome-maligna-dos-neurolepticos-e-da-distonia-aguda-pt/ 2026-09-01T17:30:15+00:00 https://pt.psychopharmacologyinstitute.com/section/discinesia-tardia-induzida-por-antipsicoticos-avaliacao-e-monitorizacao-pt/ 2026-09-01T17:30:19+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-discinesia-tardia-induzida-por-antipsicoticos-pt/ 2026-09-01T17:30:23+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-da-hiperprolactinemia-e-efeitos-colaterais-sexuais-associados-ao-uso-de-antipsicoticos-pt/ 2026-09-01T17:30:26+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-dos-efeitos-colaterais-cardiacos-do-tratamento-antipsicotico-pt/ 2026-09-01T17:30:29+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-da-hipotensao-ortostatica-e-convulsoes-induzidas-por-antipsicoticos-pt/ 2026-09-01T17:30:33+00:00 https://pt.psychopharmacologyinstitute.com/section/problemas-gastrointestinais-induzidos-por-antipsicoticos-sialorreia-e-constipacao-pt/ 2026-09-01T17:30:37+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9312-pt/ 2026-09-01T17:30:40+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-visao-geral-do-uso-de-substancias-e-do-uso-indevido-de-opioides/ 2026-09-01T17:30:48+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-a-intoxicacao-e-a-abstinencia-de-opioides/ 2026-09-01T17:30:51+00:00 https://pt.psychopharmacologyinstitute.com/section/um-guia-abrangente-para-o-tratamento-de-oud/ 2026-09-01T17:30:55+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-personalizada-do-paciente-uma-chave-para-o-tratamento-eficaz-do-oud/ 2026-09-01T17:30:59+00:00 https://pt.psychopharmacologyinstitute.com/section/metadona-para-o-tratamento-de-oud/ 2026-09-01T17:31:02+00:00 https://pt.psychopharmacologyinstitute.com/section/buprenorfina-para-o-tratamento-de-oud/ 2026-09-01T17:31:06+00:00 https://pt.psychopharmacologyinstitute.com/section/examinando-a-eficacia-da-naltrexona-de-liberacao-prolongada-para-o-uso-de-drogas/ 2026-09-01T17:31:10+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-da-naloxona-no-controle-do-oud/ 2026-09-01T17:31:14+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-inicio-do-tratamento-com-buprenorfina/ 2026-09-01T17:31:17+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-15/ 2026-09-01T17:31:21+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-introducao-ao-uso-de-medicamentos-naturais-para-transtornos-psiquiatricos/ 2026-09-01T17:31:28+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-evidencias-da-n-acetilcisteina-nac-para-transtornos-do-humor/ 2026-09-01T17:31:32+00:00 https://pt.psychopharmacologyinstitute.com/section/evidencia-de-nac-em-outros-transtornos-psiquiatricos/ 2026-09-01T17:31:36+00:00 https://pt.psychopharmacologyinstitute.com/section/inositol-indicacoes-potenciais-administracao-e-uma-vinheta-clinica/ 2026-09-01T17:31:39+00:00 https://pt.psychopharmacologyinstitute.com/section/canabidiol-evidencias-para-transtornos-psiquiatricos-e-recomendacoes-para-seu-uso/ 2026-09-01T17:31:43+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-acido-folico-e-l-metilfolato-em-transtornos-psiquiatricos-2/ 2026-09-01T17:31:48+00:00 https://pt.psychopharmacologyinstitute.com/section/ashwagandha-asw-indicacoes-potenciais-e-administracao-em-transtornos-psiquiatricos/ 2026-09-01T17:31:52+00:00 https://pt.psychopharmacologyinstitute.com/section/possiveis-combinacoes-de-medicamentos-naturais-para-transtornos-psiquiatricos/ 2026-09-01T17:31:56+00:00 https://pt.psychopharmacologyinstitute.com/section/recomendacoes-para-o-uso-de-medicamentos-naturais-em-transtornos-psiquiatricos/ 2026-09-01T17:32:01+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-2-3/ 2026-09-01T17:32:04+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-introducao-ao-uso-do-bsm-na-pratica-clinica/ 2026-09-01T17:32:11+00:00 https://pt.psychopharmacologyinstitute.com/section/bsms-ingredientes-e-doses-2/ 2026-09-01T17:32:15+00:00 https://pt.psychopharmacologyinstitute.com/section/bsms-seguranca-e-tolerabilidade/ 2026-09-01T17:32:19+00:00 https://pt.psychopharmacologyinstitute.com/section/bsms-e-potencializacao-de-medicamentos-psicotropicos/ 2026-09-01T17:32:23+00:00 https://pt.psychopharmacologyinstitute.com/section/contraindicacoes-estritas-e-relativas-para-o-uso-de-bsms-2/ 2026-09-01T17:32:27+00:00 https://pt.psychopharmacologyinstitute.com/section/bsms-e-interacoes-medicamentosas-2/ 2026-09-01T17:32:30+00:00 https://pt.psychopharmacologyinstitute.com/section/dicas-praticas-para-usar-o-bsms-na-pratica-clinica/ 2026-09-01T17:32:34+00:00 https://pt.psychopharmacologyinstitute.com/section/dosagem-empowerplus-avancada-e-nutrientes-essenciais-diarios/ 2026-09-01T17:32:38+00:00 https://pt.psychopharmacologyinstitute.com/section/iniciando-o-bsms-em-sua-pratica-clinica-um-processo-passo-a-passo-2/ 2026-09-01T17:32:42+00:00 https://pt.psychopharmacologyinstitute.com/section/outras-consideracoes-ao-usar-o-bsms/ 2026-09-01T17:32:46+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-2-2/ 2026-09-01T17:32:49+00:00 https://pt.psychopharmacologyinstitute.com/section/visao-geral-do-transtorno-do-espectro-do-autismo/ 2026-09-01T17:32:57+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-hiperatividade-motora-e-da-desatencao-no-tea-estimulantes/ 2026-09-01T17:33:01+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-hiperatividade-motora-e-da-desatencao-no-tea-nao-estimulantes/ 2026-09-01T17:33:04+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-comportamentos-repetitivos-no-tea-antidepressivos/ 2026-09-01T17:33:08+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-depressao-e-da-ansiedade-no-tea-antidepressivos-e-outras-estrategias/ 2026-09-01T17:33:12+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-irritabilidade-no-tea-risperidona-e-aripiprazol/ 2026-09-01T17:33:16+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-irritabilidade-no-tea-outros-medicamentos-antipsicoticos-e-treinamento-dos-pais/ 2026-09-01T17:33:19+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-da-irritabilidade-no-tea-estabilizadores-de-humor-e-outras-estrategias/ 2026-09-01T17:33:23+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-dos-disturbios-do-sono-no-tea-melatonina-e-outras-estrategias/ 2026-09-01T17:33:27+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-do-comprometimento-da-relacao-social-no-tea/ 2026-09-01T17:33:31+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-dos-genes-farmacocineticos-e-farmacodinamicos/ 2026-09-01T17:33:41+00:00 https://pt.psychopharmacologyinstitute.com/section/como-os-genes-farmacocineticos-influenciam-o-metabolismo-dos-medicamentos-2/ 2026-09-01T17:33:45+00:00 https://pt.psychopharmacologyinstitute.com/section/testes-farmacogeneticos-importantes-na-pratica-psiquiatrica/ 2026-09-01T17:33:48+00:00 https://pt.psychopharmacologyinstitute.com/section/dosagem-guiada-por-farmacogenetica-estrategias-para-metabolizadores-fracos-e-rapidos/ 2026-09-01T17:33:51+00:00 https://pt.psychopharmacologyinstitute.com/section/paineis-farmacogeneticos-eles-realmente-funcionam/ 2026-09-01T17:33:55+00:00 https://pt.psychopharmacologyinstitute.com/section/gene-sert-e-resposta-a-isrs-e-clinicamente-util-2/ 2026-09-01T17:33:58+00:00 https://pt.psychopharmacologyinstitute.com/section/gene-mthfr-o-elo-fraco-no-tratamento-da-depressao-por-l-metilfolato/ 2026-09-01T17:34:02+00:00 https://pt.psychopharmacologyinstitute.com/section/os-testes-geneticos-podem-causar-mais-danos-do-que-beneficios/ 2026-09-01T17:34:05+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-gerenciamento-da-dosagem-de-citalopram-em-metabolizadores-ruins-de-cyp2c19/ 2026-09-01T17:34:09+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-7/ 2026-09-01T17:34:12+00:00 https://pt.psychopharmacologyinstitute.com/section/um-historico-sobre-parassonias/ 2026-09-01T17:34:19+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-de-transtorno-alimentar-relacionado-ao-sono-sred/ 2026-09-01T17:34:23+00:00 https://pt.psychopharmacologyinstitute.com/section/sred-induzido-por-medicamentos-sonambulismo-e-direcao-com-sono/ 2026-09-01T17:34:27+00:00 https://pt.psychopharmacologyinstitute.com/section/zolpidem-e-comportamentos-complexos-amnesticos-durante-o-sono-2/ 2026-09-01T17:34:30+00:00 https://pt.psychopharmacologyinstitute.com/section/sonambulismo-induzido-por-zolpidem-e-sred/ 2026-09-01T17:34:34+00:00 https://pt.psychopharmacologyinstitute.com/section/preditores-de-risco-para-comportamentos-complexos-de-sono-relacionados-a-hipnose-2/ 2026-09-01T17:34:37+00:00 https://pt.psychopharmacologyinstitute.com/section/parassonias-em-pacientes-psiquiatricos-ambulatoriais-resultados-do-sred-2/ 2026-09-01T17:34:41+00:00 https://pt.psychopharmacologyinstitute.com/section/casos-clinicos-e-videos-2/ 2026-09-01T17:34:44+00:00 https://pt.psychopharmacologyinstitute.com/section/medicamentos-para-tdah-e-efeitos-colaterais-cardiacos-o-que-as-evidencias-realmente-mostram-pt/ 2026-09-01T17:34:56+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-e-anticoagulantes-manejo-do-risco-de-sangramento-pt/ 2026-09-01T17:35:00+00:00 https://pt.psychopharmacologyinstitute.com/section/escolha-de-antipsicoticos-em-pacientes-em-uso-de-anticoagulantes-interacoes-medicamentosas-e-alternativas-mais-seguras-pt/ 2026-09-01T17:35:03+00:00 https://pt.psychopharmacologyinstitute.com/section/estabilizadores-do-humor-e-anticoagulacao-valproato-carbamazepina-litio-e-lamotrigina-pt/ 2026-09-01T17:35:07+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-em-hemodialise-seguranca-cardiaca-e-ajustes-de-dose-pt/ 2026-09-01T17:35:11+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-em-hemodialise-estrategias-de-deposito-risco-de-qt-e-posologia-especifica-por-farmaco-pt/ 2026-09-01T17:35:15+00:00 https://pt.psychopharmacologyinstitute.com/section/estabilizadores-do-humor-em-hemodialise-posologia-de-litio-valproato-e-lamotrigina-pt/ 2026-09-01T17:35:19+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-quando-o-paciente-nao-consegue-engolir-vias-de-administracao-farmacos-disponiveis-e-orientacoes-praticas-pt/ 2026-09-01T17:35:23+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-transtorno-esquizoafetivo-infarto-do-miocardio-e-lesao-renal-aguda-pt/ 2026-09-01T17:35:27+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-principais-pt/ 2026-09-01T17:35:31+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-perinatal-superando-barreiras-e-aumentando-a-confianca-pt/ 2026-09-01T17:35:39+00:00 https://pt.psychopharmacologyinstitute.com/section/impacto-da-gravidez-na-eficacia-dos-medicamentos-e-consideracoes-posologicas-pt/ 2026-09-01T17:35:43+00:00 https://pt.psychopharmacologyinstitute.com/section/medicamentos-psiquiatricos-na-gravidez-equilibrio-entre-o-bem-estar-materno-e-fetal-pt/ 2026-09-01T17:35:46+00:00 https://pt.psychopharmacologyinstitute.com/section/litio-na-gravidez-e-amamentacao-pt/ 2026-09-01T17:35:50+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-com-ssri-durante-a-gravidez-um-caso-clinico-pt/ 2026-09-01T17:35:53+00:00 https://pt.psychopharmacologyinstitute.com/section/valproato-na-gravidez-consideracoes-fundamentais-pt/ 2026-09-01T17:35:57+00:00 https://pt.psychopharmacologyinstitute.com/section/gravidez-tdah-e-estimulantes-fazendo-uma-escolha-informada-1-manejo-do-tdah-durante-a-gravidez-equilibrando-riscos-e-beneficios-2-seguranca-dos-estimulantes-na-gravidez-perspectivas-para-uma-decisao-i/ 2026-09-01T17:36:01+00:00 https://pt.psychopharmacologyinstitute.com/section/recursos-em-psiquiatria-perinatal-ampliando-sua-expertise-pt/ 2026-09-01T17:36:05+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-8909-pt/ 2026-09-01T17:36:08+00:00 https://pt.psychopharmacologyinstitute.com/section/doencas-fisicas-e-transtornos-por-uso-de-substancias-uma-relacao-bidirecional-pt/ 2026-09-01T17:36:15+00:00 https://pt.psychopharmacologyinstitute.com/section/complicacoes-hepaticas-nos-transtornos-por-uso-de-substancias-fatores-de-risco-e-progressao-da-doenca-pt/ 2026-09-01T17:36:19+00:00 https://pt.psychopharmacologyinstitute.com/section/doenca-hepatica-e-maud-priorizacao-de-dissulfiram-naltrexona-e-acamprosato-pt/ 2026-09-01T17:36:23+00:00 https://pt.psychopharmacologyinstitute.com/section/doenca-hepatica-buprenorfina-metadona-e-agentes-para-cessacao-do-tabagismo-pt/ 2026-09-01T17:36:27+00:00 https://pt.psychopharmacologyinstitute.com/section/hiv-hepatite-c-e-dependencia-ajuste-de-buprenorfina-metadona-naltrexona-e-dissulfiram-com-antivirais-pt/ 2026-09-01T17:36:31+00:00 https://pt.psychopharmacologyinstitute.com/section/insuficiencia-renal-e-farmacoterapia-para-dependencia-quimica-ajuste-de-naltrexona-acamprosato-gabapentina-e-topiramato-pt/ 2026-09-01T17:36:35+00:00 https://pt.psychopharmacologyinstitute.com/section/dpoc-apneia-do-sono-e-farmacoterapia-da-dependencia-quimica-metadona-buprenorfina-gabapentina-e-baclofeno-pt/ 2026-09-01T17:36:40+00:00 https://pt.psychopharmacologyinstitute.com/section/doenca-cardiovascular-e-farmacoterapia-da-dependencia-quimica-risco-de-qtc-cessacao-do-tabagismo-e-seguranca-do-dissulfiram-pt/ 2026-09-01T17:36:44+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-transtorno-por-uso-de-alcool-com-transaminases-elevadas-pt/ 2026-09-01T17:36:48+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-pt/ 2026-09-01T17:36:52+00:00 https://pt.psychopharmacologyinstitute.com/section/a-ciencia-da-arte-da-psicofarmacoterapia/ 2026-09-01T17:36:59+00:00 https://pt.psychopharmacologyinstitute.com/section/a-teoria-biologica-da-doenca-e-o-estigma/ 2026-09-01T17:37:03+00:00 https://pt.psychopharmacologyinstitute.com/section/alianca-farmacoterapeutica-preferencias-de-tratamento-e-comunicacao/ 2026-09-01T17:37:06+00:00 https://pt.psychopharmacologyinstitute.com/section/habilidades-de-psicoterapia-na-pratica-cotidiana-psicoterapia-medica-comum/ 2026-09-01T17:37:10+00:00 https://pt.psychopharmacologyinstitute.com/section/o-caso-de-m-parte-1/ 2026-09-01T17:37:14+00:00 https://pt.psychopharmacologyinstitute.com/section/o-caso-de-m-parte-2/ 2026-09-01T17:37:18+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-6/ 2026-09-01T17:37:21+00:00 https://pt.psychopharmacologyinstitute.com/section/prescricao-na-era-da-psiquiatria-biomedica-uma-introducao/ 2026-09-01T17:37:29+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-o-problema-da-resistencia-ao-tratamento/ 2026-09-01T17:37:33+00:00 https://pt.psychopharmacologyinstitute.com/section/adotando-uma-perspectiva-integradora/ 2026-09-01T17:37:37+00:00 https://pt.psychopharmacologyinstitute.com/section/conceitos-psicodinamicos-basicos/ 2026-09-01T17:37:41+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-introducao-a-psicofarmacologia-psicodinamica/ 2026-09-01T17:37:44+00:00 https://pt.psychopharmacologyinstitute.com/section/evitando-a-divisao-mente-corpo-fontes-do-pensamento-dualista/ 2026-09-01T17:37:48+00:00 https://pt.psychopharmacologyinstitute.com/section/integracao-mente-corpo-no-tratamento-psiquiatrico/ 2026-09-01T17:37:51+00:00 https://pt.psychopharmacologyinstitute.com/section/conhecer-o-paciente/ 2026-09-01T17:37:55+00:00 https://pt.psychopharmacologyinstitute.com/section/atender-a-ambivalencia-do-paciente/ 2026-09-01T17:37:59+00:00 https://pt.psychopharmacologyinstitute.com/section/cultivar-uma-alianca-terapeutica/ 2026-09-01T17:38:03+00:00 https://pt.psychopharmacologyinstitute.com/section/abordagem-de-usos-contraterapeuticos-de-medicamentos-e-contratransferencia/ 2026-09-01T17:38:07+00:00 https://pt.psychopharmacologyinstitute.com/section/vinhetas-clinicas/ 2026-09-01T17:38:11+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-10/ 2026-09-01T17:38:14+00:00 https://pt.psychopharmacologyinstitute.com/section/funcao-cognitiva-e-trajetorias-de-resposta-ao-tratamento-na-esquizofrenia-de-primeiro-episodio-evidencias-de-um-estudo-de-coorte-prospectivo-pt/ 2026-09-01T17:38:23+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-para-o-tratamento-de-adultos-com-transtorno-depressivo-maior-na-fase-de-manutencao-uma-revisao-sistematica-e-metanalise-em-rede-pt/ 2026-09-01T17:38:27+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-de-augmentacao-para-resistencia-a-clozapina-uma-revisao-sistematica-e-meta-analise-pt/ 2026-09-01T17:38:31+00:00 https://pt.psychopharmacologyinstitute.com/section/a-proteina-c-reativa-pode-prever-a-eficacia-dos-ssris-na-pratica-clinica-um-estudo-de-coorte-com-grandes-amostras-no-mundo-real-pt/ 2026-09-01T17:38:34+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-do-ansiolitico-silexan-no-sono-uma-revisao-narrativa-pt/ 2026-09-01T17:38:39+00:00 https://pt.psychopharmacologyinstitute.com/section/associacoes-entre-uso-de-antipsicoticos-uso-de-substancias-e-risco-de-recaida-em-pacientes-com-esquizofrenia-evidencias-do-mundo-real-de-2-coortes-nacionais-pt/ 2026-09-01T17:38:46+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-novos-e-emergentes-para-depressao-maior-pt/ 2026-09-01T17:38:50+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-de-uma-intervencao-de-autogestao-baseada-em-smartphone-para-individuos-com-transtorno-bipolar-sobre-recaida-carga-sintomatica-e-qualidade-de-vida-pt/ 2026-09-01T17:38:54+00:00 https://pt.psychopharmacologyinstitute.com/section/padroes-de-uso-de-cigarros-eletronicos-sabores-e-caracteristicas-dos-dispositivos-associados-a-cessacao-do-tabagismo-em-uma-amostra-de-adultos-nos-eua-usando-cigarros-eletronicos-em-uma-tentativa-de-c/ 2026-09-01T17:38:57+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-dos-testes-farmacogenomicos-para-interacoes-medicamento-gene-na-selecao-de-medicamentos-e-remissao-de-sintomas-no-transtorno-depressivo-maior-o-ensaio-clinico-randomizado-prime-care-pt/ 2026-09-01T17:39:01+00:00 https://pt.psychopharmacologyinstitute.com/section/haloperidol-para-o-tratamento-do-delirium-em-pacientes-na-uti-pt/ 2026-09-01T17:39:09+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-antidepressivos-durante-a-gravidez-e-o-risco-de-diabetes-gestacional-uma-revisao-sistematica-e-meta-analise-pt/ 2026-09-01T17:39:13+00:00 https://pt.psychopharmacologyinstitute.com/section/risco-de-doencas-cardiovasculares-associado-aos-medicamentos-utilizados-no-transtorno-de-deficit-de-atencao-hiperatividade-uma-revisao-sistematica-e-meta-analise-pt/ 2026-09-01T17:39:17+00:00 https://pt.psychopharmacologyinstitute.com/section/cannabis-conectividade-e-transicao-para-a-vida-adulta-associacoes-entre-o-uso-de-cannabis-e-a-conectividade-do-cortex-cingulado-anterior-durante-a-transicao-para-a-idade-adulta-pt/ 2026-09-01T17:39:20+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-contraceptivos-hormonais-e-antidepressivos-e-riscos-de-comportamento-suicida-e-acidentes-em-mulheres-com-transtornos-pre-menstruais-um-estudo-de-coorte-nacional-pt/ 2026-09-01T17:39:24+00:00 https://pt.psychopharmacologyinstitute.com/section/eficacia-comparativa-seguranca-e-aceitabilidade-da-pimavanserin-e-outros-antipsicoticos-atipicos-na-psicose-da-doenca-de-parkinson-revisao-sistematica-e-meta-analise-em-rede-pt/ 2026-09-01T17:39:33+00:00 https://pt.psychopharmacologyinstitute.com/section/antagonistas-duais-dos-receptores-de-orexina-para-o-tratamento-da-insonia-uma-revisao-sistematica-e-meta-analise-de-ensaios-clinicos-randomizados-duplo-cegos-e-controlados-por-placebo-com-suvorexanto/ 2026-09-01T17:39:36+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-farmacologicos-para-o-craving-de-cocaina-qual-e-o-caminho-a-seguir-uma-revisao-sistematica-pt/ 2026-09-01T17:39:40+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-de-terceira-geracao-em-pacientes-com-esquizofrenia-e-nao-responsividade-ou-intolerancia-ao-regime-com-clozapina-quais-sao-as-evidencias-pt/ 2026-09-01T17:39:44+00:00 https://pt.psychopharmacologyinstitute.com/section/olanzapina-samidorfano-em-adultos-jovens-com-esquizofrenia-transtorno-esquizofreniforme-ou-transtorno-bipolar-i-em-fase-inicial-da-doenca-resultados-do-estudo-randomizado-e-controlado-enlighten-early/ 2026-09-01T17:39:48+00:00 https://pt.psychopharmacologyinstitute.com/section/a-doenca-de-cade-e-alem-diagnostico-equivocado-uso-de-antidepressivos-e-uma-definicao-proposta-para-o-transtorno-do-espectro-bipolar-pt/ 2026-09-01T17:39:55+00:00 https://pt.psychopharmacologyinstitute.com/section/recomendacoes-da-canadian-network-for-mood-and-anxiety-treatments-canmat-e-da-international-society-for-bipolar-disorders-isbd-para-o-manejo-de-pacientes-com-transtorno-bipolar-com-apresentacoes-mista/ 2026-09-01T17:39:59+00:00 https://pt.psychopharmacologyinstitute.com/section/considerando-as-limitacoes-metodologicas-na-base-de-evidencias-dos-antidepressivos-para-depressao-uma-reanalise-de-uma-metanalise-em-rede-pt/ 2026-09-01T17:40:03+00:00 https://pt.psychopharmacologyinstitute.com/section/distinguindo-recaida-de-sindrome-de-descontinuacao-de-antidepressivos-pratica-clinica-e-estudos-de-descontinuacao-de-antidepressivos-pt/ 2026-09-01T17:40:06+00:00 https://pt.psychopharmacologyinstitute.com/section/diretrizes-de-2018-da-canadian-network-for-mood-and-anxiety-treatments-canmat-e-da-international-society-for-bipolar-disorders-isbd-para-o-manejo-de-pacientes-com-transtorno-bipolar-pt/ 2026-09-01T17:40:11+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-da-brexanolona-nos-sintomas-depressivos-ansiedade-e-insonia-no-pos-parto-pt/ 2026-09-01T17:40:19+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-da-coprescricao-de-aripiprazol-nos-niveis-de-prolactina-em-pacientes-com-esquizofrenia-e-diabetes-tipo-2-pt/ 2026-09-01T17:40:23+00:00 https://pt.psychopharmacologyinstitute.com/section/sindromes-tardios-manifestacoes-clinicas-e-estrategias-terapeuticas-pt/ 2026-09-01T17:40:27+00:00 https://pt.psychopharmacologyinstitute.com/section/efeito-dos-testes-de-farmacogenomica-nos-desfechos-clinicos-no-transtorno-depressivo-maior-pt/ 2026-09-01T17:40:30+00:00 https://pt.psychopharmacologyinstitute.com/section/o-impacto-do-fator-estimulador-de-colonias-nos-desfechos-do-redesafio-com-clozapina-pt/ 2026-09-01T17:40:34+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-aines-para-reducao-do-risco-de-delirium-pt/ 2026-09-01T17:40:43+00:00 https://pt.psychopharmacologyinstitute.com/section/vitimizacao-em-relacao-a-violencia-na-esquizofrenia-pt/ 2026-09-01T17:40:46+00:00 https://pt.psychopharmacologyinstitute.com/section/zuranolona-para-o-tratamento-da-depressao-pos-parto-pt/ 2026-09-01T17:40:50+00:00 https://pt.psychopharmacologyinstitute.com/section/apatia-associada-a-antidepressivos-pt/ 2026-09-01T17:40:54+00:00 https://pt.psychopharmacologyinstitute.com/section/risco-de-malformacoes-em-lactentes-apos-exposicao-a-benzodiazepinicos-pt/ 2026-09-01T17:40:58+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-tabaco-dependencia-a-nicotina-e-cessacao-do-tabagismo-em-adultos-com-psicose-pt/ 2026-09-01T17:41:06+00:00 https://pt.psychopharmacologyinstitute.com/section/o-tratamento-farmacologico-do-transtorno-obsessivo-compulsivo-pt/ 2026-09-01T17:41:10+00:00 https://pt.psychopharmacologyinstitute.com/section/risco-de-disfuncao-sexual-pos-ssri-irreversivel-com-antidepressivos-pt/ 2026-09-01T17:41:13+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-preventivos-dos-antagonistas-duais-dos-receptores-de-orexina-no-delirium-pt/ 2026-09-01T17:41:17+00:00 https://pt.psychopharmacologyinstitute.com/section/disturbios-do-sono-na-doenca-de-parkinson-pt/ 2026-09-01T17:41:21+00:00 https://pt.psychopharmacologyinstitute.com/section/complicacoes-neonatais-e-na-gravidez-associadas-a-depressao-materna-ou-a-exposicao-a-antidepressivos-pt/ 2026-09-01T17:41:29+00:00 https://pt.psychopharmacologyinstitute.com/section/descontinuacao-de-antidepressivos-durante-a-gestacao-e-desfechos-psiquiatricos-no-pos-parto-pt/ 2026-09-01T17:41:33+00:00 https://pt.psychopharmacologyinstitute.com/section/potencializacao-com-litio-no-tratamento-do-transtorno-depressivo-maior-pt/ 2026-09-01T17:41:38+00:00 https://pt.psychopharmacologyinstitute.com/section/seguranca-dos-antipsicoticos-em-doencas-hepaticas-pt/ 2026-09-01T17:41:42+00:00 https://pt.psychopharmacologyinstitute.com/section/polifarmacia-e-medicamentos-inapropriados-em-associacao-com-antidepressivos-em-idosos-pt/ 2026-09-01T17:41:45+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-e-risco-de-pancreatite-aguda-pt/ 2026-09-01T17:41:53+00:00 https://pt.psychopharmacologyinstitute.com/section/clozapina-e-sua-augmentacao-com-ect-na-esquizofrenia-ultrarrefrataria-ao-tratamento-pt/ 2026-09-01T17:41:56+00:00 https://pt.psychopharmacologyinstitute.com/section/risco-de-tentativas-de-suicidio-e-suicidio-associados-a-benzodiazepinicos-pt/ 2026-09-01T17:42:01+00:00 https://pt.psychopharmacologyinstitute.com/section/potenciais-beneficios-do-silexan-para-a-sindrome-pos-covid-19-pt/ 2026-09-01T17:42:06+00:00 https://pt.psychopharmacologyinstitute.com/section/a-trazodona-deve-ser-a-terapia-de-primeira-linha-para-a-insonia-pt/ 2026-09-01T17:42:10+00:00 https://pt.psychopharmacologyinstitute.com/section/concentracoes-plasmaticas-de-ssri-snri-apos-cirurgia-bariatrica-e-efeitos-sobre-os-sintomas-depressivos-pt/ 2026-09-01T17:42:18+00:00 https://pt.psychopharmacologyinstitute.com/section/psicodelicos-como-terapeuticas-transformadoras-pt/ 2026-09-01T17:42:22+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-antidepressivos-em-pacientes-com-depressao-comorbida-e-doencas-clinicas-pt/ 2026-09-01T17:42:26+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-de-daridorexanto-no-manejo-da-insonia-cronica-pt/ 2026-09-01T17:42:30+00:00 https://pt.psychopharmacologyinstitute.com/section/uma-agenda-internacional-de-pesquisa-para-a-esquizofrenia-resistente-a-clozapina-pt/ 2026-09-01T17:42:33+00:00 https://pt.psychopharmacologyinstitute.com/section/sintomas-de-insonia-e-o-risco-de-avc-no-health-and-retirement-study-pt/ 2026-09-01T17:42:41+00:00 https://pt.psychopharmacologyinstitute.com/section/eficacia-a-longo-prazo-dos-antipsicoticos-em-adultos-com-esquizofrenia-pt/ 2026-09-01T17:42:45+00:00 https://pt.psychopharmacologyinstitute.com/section/seguranca-comparativa-de-antipsicoticos-orais-para-eventos-adversos-em-adultos-apos-cirurgia-pt/ 2026-09-01T17:42:48+00:00 https://pt.psychopharmacologyinstitute.com/section/cannabis-medicinal-no-tratamento-da-doenca-de-parkinson-pt/ 2026-09-01T17:42:52+00:00 https://pt.psychopharmacologyinstitute.com/section/prevalencia-de-anormalidades-neurorradiologicas-no-primeiro-episodio-psicotico-pt/ 2026-09-01T17:42:56+00:00 https://pt.psychopharmacologyinstitute.com/section/cariprazina-como-tratamento-adjuvante-do-transtorno-depressivo-maior-pt/ 2026-09-01T17:43:04+00:00 https://pt.psychopharmacologyinstitute.com/section/eficacia-do-tratamento-com-risperidona-em-baixas-doses-para-o-delirium-pos-cirurgico-em-pacientes-idosos-pt/ 2026-09-01T17:43:08+00:00 https://pt.psychopharmacologyinstitute.com/section/eficacia-da-memantina-no-tratamento-da-tricotilomania-e-do-transtorno-de-escoriacao-pt/ 2026-09-01T17:43:11+00:00 https://pt.psychopharmacologyinstitute.com/section/transtornos-psiquiatricos-e-risco-subsequente-de-doenca-cardiovascular-pt/ 2026-09-01T17:43:15+00:00 https://pt.psychopharmacologyinstitute.com/section/efetividade-no-mundo-real-dos-tratamentos-farmacologicos-para-o-transtorno-bipolar-pt/ 2026-09-01T17:43:19+00:00 https://pt.psychopharmacologyinstitute.com/section/revisitando-o-droperidol-no-manejo-da-agitacao-pt/ 2026-09-01T17:43:27+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-a-interacao-entre-antidepressivos-e-psicoterapia-pt/ 2026-09-01T17:43:31+00:00 https://pt.psychopharmacologyinstitute.com/section/descontinuacao-de-benzodiazepinicos-e-farmacos-z-em-pacientes-idosos-hospitalizados-pt/ 2026-09-01T17:43:35+00:00 https://pt.psychopharmacologyinstitute.com/section/anosmia-em-pacientes-com-covid-19-impactos-e-potenciais-tratamentos-pt/ 2026-09-01T17:43:39+00:00 https://pt.psychopharmacologyinstitute.com/section/a-olanzapina-em-altas-doses-e-uma-opcao-para-a-esquizofrenia-resistente-ao-tratamento-pt/ 2026-09-01T17:43:43+00:00 https://pt.psychopharmacologyinstitute.com/section/clozapina-e-sintomas-semelhantes-ao-toc-qual-e-a-conexao-pt/ 2026-09-01T17:43:51+00:00 https://pt.psychopharmacologyinstitute.com/section/o-ganho-de-peso-induzido-pelo-valproato-e-dose-dependente-pt/ 2026-09-01T17:43:55+00:00 https://pt.psychopharmacologyinstitute.com/section/alem-dos-antidepressivos-agonistas-dopaminergicos-para-depressao-resistente-ao-tratamento-pt/ 2026-09-01T17:43:58+00:00 https://pt.psychopharmacologyinstitute.com/section/o-delirium-aumenta-o-risco-de-demencia-pt/ 2026-09-01T17:44:02+00:00 https://pt.psychopharmacologyinstitute.com/section/novas-diretrizes-clinicas-para-o-tratamento-do-transtorno-por-uso-de-estimulantes-pt/ 2026-09-01T17:44:06+00:00 https://pt.psychopharmacologyinstitute.com/section/pneumonia-na-esquizofrenia-quais-antipsicoticos-representam-o-maior-risco-pt/ 2026-09-01T17:44:13+00:00 https://pt.psychopharmacologyinstitute.com/section/ganho-de-peso-induzido-por-antipsicoticos-melhores-estrategias-de-manejo-pt/ 2026-09-01T17:44:17+00:00 https://pt.psychopharmacologyinstitute.com/section/qual-e-a-faixa-terapeutica-ideal-para-o-litio-no-transtorno-bipolar-pt/ 2026-09-01T17:44:21+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-vitaminas-do-complexo-b-e-cognicao-existe-uma-conexao-pt/ 2026-09-01T17:44:24+00:00 https://pt.psychopharmacologyinstitute.com/section/os-efeitos-antidepressivos-do-exercicio-uma-estrutura-conceitual-proposta-pt/ 2026-09-01T17:44:28+00:00 https://pt.psychopharmacologyinstitute.com/section/os-agonistas-do-glp-1-podem-tratar-o-transtorno-por-uso-de-alcool-pt/ 2026-09-01T17:44:36+00:00 https://pt.psychopharmacologyinstitute.com/section/quais-antidepressivos-causam-maior-ganho-de-peso-pt/ 2026-09-01T17:44:40+00:00 https://pt.psychopharmacologyinstitute.com/section/os-antidepressivos-aumentam-o-risco-de-quedas-em-idosos-pt/ 2026-09-01T17:44:44+00:00 https://pt.psychopharmacologyinstitute.com/section/cetamina-e-escetamina-na-depressao-bipolar-pt/ 2026-09-01T17:44:48+00:00 https://pt.psychopharmacologyinstitute.com/section/o-aripiprazol-e-realmente-mais-seguro-do-ponto-de-vista-metabolico-do-que-a-olanzapina-pt/ 2026-09-01T17:44:51+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-de-acao-prolongada-superiores-na-reducao-da-mortalidade-na-esquizofrenia-pt/ 2026-09-01T17:44:59+00:00 https://pt.psychopharmacologyinstitute.com/section/manutencao-do-transtorno-bipolar-qual-e-a-faixa-de-dose-ideal-pt/ 2026-09-01T17:45:04+00:00 https://pt.psychopharmacologyinstitute.com/section/doenca-de-alzheimer-olanzapina-vs-risperidona-para-scpd-pt/ 2026-09-01T17:45:09+00:00 https://pt.psychopharmacologyinstitute.com/section/a-lisdexanfetamina-pode-tratar-o-transtorno-por-uso-de-metanfetamina-pt/ 2026-09-01T17:45:13+00:00 https://pt.psychopharmacologyinstitute.com/section/cronoterapia-os-ritmos-circadianos-podem-influenciar-a-eficacia-do-tratamento-pt/ 2026-09-01T17:45:17+00:00 https://pt.psychopharmacologyinstitute.com/section/lurasidona-para-depressao-bipolar-qual-e-a-dose-otima-pt/ 2026-09-01T17:45:25+00:00 https://pt.psychopharmacologyinstitute.com/section/transtorno-por-uso-de-alcool-o-dissulfiram-deve-ser-de-primeira-linha-pt/ 2026-09-01T17:45:29+00:00 https://pt.psychopharmacologyinstitute.com/section/melatonina-trazodona-ou-doxepina-para-disturbios-do-sono-pt/ 2026-09-01T17:45:33+00:00 https://pt.psychopharmacologyinstitute.com/section/alertas-de-qt-para-antipsicoticos-refletem-o-risco-cardiaco-real-pt/ 2026-09-01T17:45:38+00:00 https://pt.psychopharmacologyinstitute.com/section/estamos-supervalorizando-ou-subutilizando-a-clozapina-na-psiquiatria-clozapina-versus-antipsicoticos-de-segunda-geracao-na-esquizofrenia-resistente-ao-tratamento-pt/ 2026-09-01T17:45:42+00:00 https://pt.psychopharmacologyinstitute.com/section/algoritmo-para-esquizofrenia-selecao-de-antipsicotico-em-primeiros-episodios-pt/ 2026-09-01T17:45:49+00:00 https://pt.psychopharmacologyinstitute.com/section/os-efeitos-colaterais-dos-ssri-melhoram-com-o-tempo-pt/ 2026-09-01T17:45:53+00:00 https://pt.psychopharmacologyinstitute.com/section/torsades-de-pointes-impacto-de-antidepressivos-e-antipsicoticos-pt/ 2026-09-01T17:45:58+00:00 https://pt.psychopharmacologyinstitute.com/section/os-psicodelicos-sao-eficazes-no-tratamento-dos-transtornos-por-uso-de-substancias-pt/ 2026-09-01T17:46:02+00:00 https://pt.psychopharmacologyinstitute.com/section/a-neurociencia-por-tras-dos-efeitos-do-cha-na-saude-mental-pt/ 2026-09-01T17:46:06+00:00 https://pt.psychopharmacologyinstitute.com/section/lumateperona-para-depressao-com-caracteristicas-mistas-e-eficaz-pt/ 2026-09-01T17:46:15+00:00 https://pt.psychopharmacologyinstitute.com/section/ganho-de-peso-induzido-por-antipsicoticos-os-agonistas-do-glp-1-sao-eficazes-pt/ 2026-09-01T17:46:19+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-resistente-ao-tratamento-litio-vs-quetiapina-para-augmentacao-pt/ 2026-09-01T17:46:23+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-pioram-a-cognicao-em-pacientes-com-demencia-pt/ 2026-09-01T17:46:27+00:00 https://pt.psychopharmacologyinstitute.com/section/probioticos-e-prebioticos-para-depressao-e-ansiedade-o-intestino-pode-curar-a-mente-pt/ 2026-09-01T17:46:31+00:00 https://pt.psychopharmacologyinstitute.com/section/integrate-novas-diretrizes-de-tratamento-para-esquizofrenia-pt/ 2026-09-01T17:46:40+00:00 https://pt.psychopharmacologyinstitute.com/section/a-lurasidona-e-eficaz-para-a-depressao-bipolar-com-ansiedade-comorbida-pt/ 2026-09-01T17:46:44+00:00 https://pt.psychopharmacologyinstitute.com/section/os-ssris-aumentam-o-risco-de-sangramento-maior-com-anticoagulantes-orais-pt/ 2026-09-01T17:46:48+00:00 https://pt.psychopharmacologyinstitute.com/section/sertralina-em-pacientes-com-doenca-cardiovascular-o-que-os-psiquiatras-precisam-saber-pt/ 2026-09-01T17:46:53+00:00 https://pt.psychopharmacologyinstitute.com/section/o-consumo-elevado-de-sal-aumenta-o-risco-de-depressao-e-ansiedade-pt/ 2026-09-01T17:46:57+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-bipolar-resistente-ao-tratamento-o-pramipexol-adjuvante-e-uma-opcao-pt/ 2026-09-01T17:47:05+00:00 https://pt.psychopharmacologyinstitute.com/section/a-semaglutida-reverte-o-ganho-de-peso-induzido-pela-clozapina-na-esquizofrenia-resultados-do-estudo-coast-pt/ 2026-09-01T17:47:09+00:00 https://pt.psychopharmacologyinstitute.com/section/psicose-induzida-por-cannabis-quais-antipsicoticos-previnem-melhor-a-hospitalizacao-pt/ 2026-09-01T17:47:14+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-resistente-ao-tratamento-quais-sao-os-tratamentos-mais-eficazes-uma-metanalise-em-rede-pt/ 2026-09-01T17:47:19+00:00 https://pt.psychopharmacologyinstitute.com/section/a-microbiota-intestinal-esta-alterada-na-depressao-e-na-ansiedade-pt/ 2026-09-01T17:47:23+00:00 https://pt.psychopharmacologyinstitute.com/section/novas-diretrizes-para-monitorizacao-do-anc-em-pacientes-em-uso-de-clozapina-pt/ 2026-09-01T17:47:31+00:00 https://pt.psychopharmacologyinstitute.com/section/posologia-da-cariprazina-no-transtorno-bipolar-em-adultos-idosos-pt/ 2026-09-01T17:47:35+00:00 https://pt.psychopharmacologyinstitute.com/section/semaglutida-para-o-transtorno-por-uso-de-alcool-novos-dados-de-ecr-pt/ 2026-09-01T17:47:39+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-geriatrica-otimizacao-de-estrategias-e-desafios-comuns-pt/ 2026-09-01T17:47:43+00:00 https://pt.psychopharmacologyinstitute.com/section/o-acafrao-e-tao-eficaz-quanto-os-ssris-para-depressao-e-ansiedade-nova-meta-analise-pt/ 2026-09-01T17:47:47+00:00 https://pt.psychopharmacologyinstitute.com/section/qual-e-a-eficacia-do-karxt-xanomeline-trospium-na-esquizofrenia-nnt-e-nnh-explicados-pt/ 2026-09-01T17:47:56+00:00 https://pt.psychopharmacologyinstitute.com/section/fototerapia-de-alta-intensidade-na-depressao-bipolar-recomendacoes-clinicas-da-isbd-pt/ 2026-09-01T17:48:00+00:00 https://pt.psychopharmacologyinstitute.com/section/haloperidol-iv-as-preocupacoes-com-a-seguranca-cardiaca-sao-exageradas-pt/ 2026-09-01T17:48:04+00:00 https://pt.psychopharmacologyinstitute.com/section/vareniclina-e-bupropiona-eficazes-no-tratamento-do-transtorno-por-uso-de-alcool-pt/ 2026-09-01T17:48:08+00:00 https://pt.psychopharmacologyinstitute.com/section/a-ashwagandha-e-eficaz-no-comprometimento-cognitivo-leve-pt/ 2026-09-01T17:48:13+00:00 https://pt.psychopharmacologyinstitute.com/section/o-ondansetron-e-eficaz-para-sintomas-negativos-na-esquizofrenia-pt/ 2026-09-01T17:48:21+00:00 https://pt.psychopharmacologyinstitute.com/section/orotato-de-litio-tratamento-revolucionario-para-a-doenca-de-alzheimer-pt/ 2026-09-01T17:48:24+00:00 https://pt.psychopharmacologyinstitute.com/section/e-possivel-prever-quem-responde-aos-estabilizadores-de-humor-pt/ 2026-09-01T17:48:28+00:00 https://pt.psychopharmacologyinstitute.com/section/a-augmentacao-de-ssri-e-superior-a-otimizacao-da-dose-pt/ 2026-09-01T17:48:32+00:00 https://pt.psychopharmacologyinstitute.com/section/a-trazodona-e-segura-para-a-insonia-em-pacientes-com-transtorno-por-uso-de-alcool-pt/ 2026-09-01T17:48:36+00:00 https://pt.psychopharmacologyinstitute.com/section/troca-de-antipsicoticos-orais-seis-estrategias-e-dicas-pt/ 2026-09-01T17:48:44+00:00 https://pt.psychopharmacologyinstitute.com/section/desprescricao-de-antipsicoticos-apos-delirium-por-que-e-importante-pt/ 2026-09-01T17:48:48+00:00 https://pt.psychopharmacologyinstitute.com/section/overdose-por-xilazina-tranq-dope-o-que-os-clinicos-precisam-saber-pt/ 2026-09-01T17:48:53+00:00 https://pt.psychopharmacologyinstitute.com/section/o-pramipexol-e-eficaz-no-tratamento-da-depressao-resistente-ao-tratamento-pt/ 2026-09-01T17:48:57+00:00 https://pt.psychopharmacologyinstitute.com/section/os-medicamentos-genericos-sao-verdadeiramente-intercambiaveis-com-os-originais-pt/ 2026-09-01T17:49:00+00:00 https://pt.psychopharmacologyinstitute.com/section/esquizofrenia-resistente-ao-tratamento-deve-considerar-olanzapina-em-alta-dose-em-vez-de-clozapina-pt/ 2026-09-01T17:49:08+00:00 https://pt.psychopharmacologyinstitute.com/section/potencializacao-vs-troca-de-antidepressivo-na-depressao-geriatrica-principais-achados-do-ensaio-optimum-pt/ 2026-09-01T17:49:11+00:00 https://pt.psychopharmacologyinstitute.com/section/os-agonistas-do-glp-1-podem-elevar-os-niveis-de-litio-pt/ 2026-09-01T17:49:15+00:00 https://pt.psychopharmacologyinstitute.com/section/podem-os-marcadores-inflamatorios-orientar-a-selecao-do-tratamento-antidepressivo-pt/ 2026-09-01T17:49:19+00:00 https://pt.psychopharmacologyinstitute.com/section/transtorno-de-panico-o-propranolol-e-util-para-os-sintomas-somaticos-iniciais-pt/ 2026-09-01T17:49:22+00:00 https://pt.psychopharmacologyinstitute.com/section/reducao-gradual-de-benzodiazepinicos-principais-conclusoes-das-novas-diretrizes-pt/ 2026-09-01T17:49:30+00:00 https://pt.psychopharmacologyinstitute.com/section/glp-1-na-esquizofrenia-devemos-prescrever-semaglutida-para-o-manejo-metabolico-pt/ 2026-09-01T17:49:33+00:00 https://pt.psychopharmacologyinstitute.com/section/acido-eicosapentaenoico-eficaz-como-adjuvante-na-drt-pt/ 2026-09-01T17:49:37+00:00 https://pt.psychopharmacologyinstitute.com/section/dietas-cetogenicas-em-psiquiatria-novos-resultados-de-meta-analise-pt/ 2026-09-01T17:49:41+00:00 https://pt.psychopharmacologyinstitute.com/section/comparacao-de-estrategias-de-desprescricao-de-antidepressivos-resultados-de-nova-meta-analise-pt/ 2026-09-01T17:49:44+00:00 https://pt.psychopharmacologyinstitute.com/section/xanomeline-trospium-a-longo-prazo-a-eficacia-e-a-seguranca-se-mantem-apos-um-ano-pt/ 2026-09-01T17:49:51+00:00 https://pt.psychopharmacologyinstitute.com/section/trazodona-para-insonia-e-depressao-comorbida-as-diretrizes-da-aasm-sao-relevantes-pt/ 2026-09-01T17:49:54+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-no-transtorno-bipolar-mais-seguros-do-que-se-pensava-quando-novos-dados-desafiam-conviccoes-estabelecidas-pt/ 2026-09-01T17:49:58+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-geriatrica-foco-na-inflamacao-pt/ 2026-09-01T17:50:02+00:00 https://pt.psychopharmacologyinstitute.com/section/qual-e-a-prevalencia-de-uso-indevido-e-desvio-de-estimulantes-em-pacientes-com-tdah-pt/ 2026-09-01T17:50:06+00:00 https://pt.psychopharmacologyinstitute.com/section/os-z-drugs-sao-seguros-no-primeiro-trimestre-de-gestacao-pt/ 2026-09-01T17:50:13+00:00 https://pt.psychopharmacologyinstitute.com/section/declinio-renal-induzido-pelo-litio-os-inibidores-de-sglt2-podem-ajudar-pt/ 2026-09-01T17:50:17+00:00 https://pt.psychopharmacologyinstitute.com/section/esquizofrenia-qual-dos-sete-antipsicoticos-se-destaca-em-eficacia-aguda-e-seguranca-pt/ 2026-09-01T17:50:21+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-leve-suplementos-e-fitoterapicos-sao-opcoes-razoaveis-de-primeira-linha-pt/ 2026-09-01T17:50:25+00:00 https://pt.psychopharmacologyinstitute.com/section/psicose-induzida-por-substancias-quem-mantem-o-uso-de-antipsicoticos-a-longo-prazo-pt/ 2026-09-01T17:50:28+00:00 https://pt.psychopharmacologyinstitute.com/section/primeiro-episodio-psicotico-em-mulheres-qual-e-o-antipsicotico-de-escolha-pt/ 2026-09-01T17:50:36+00:00 https://pt.psychopharmacologyinstitute.com/section/esquizofrenia-resistente-ao-tratamento-o-que-funciona-quando-a-clozapina-nao-e-uma-opcao-pt/ 2026-09-01T17:50:40+00:00 https://pt.psychopharmacologyinstitute.com/section/medicamentos-para-insonia-qual-e-o-real-potencial-de-abuso-na-pratica-clinica-pt/ 2026-09-01T17:50:43+00:00 https://pt.psychopharmacologyinstitute.com/section/cetamina-e-superior-ao-midazolam-para-a-depressao-pt/ 2026-09-01T17:50:47+00:00 https://pt.psychopharmacologyinstitute.com/section/antocianinas-e-funcao-cognitiva-o-que-a-evidencia-mostra-pt/ 2026-09-01T17:50:51+00:00 https://pt.psychopharmacologyinstitute.com/section/catatonia-os-antipsicoticos-devem-ser-sempre-evitados-pt/ 2026-09-01T17:50:58+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-na-depressao-bipolar-abordando-a-controversia-pt/ 2026-09-01T17:51:02+00:00 https://pt.psychopharmacologyinstitute.com/section/voce-deve-iniciar-clozapina-apos-apenas-um-antipsicotico-sem-resposta-pt/ 2026-09-01T17:51:06+00:00 https://pt.psychopharmacologyinstitute.com/section/o-consumo-de-refrigerantes-esta-associado-ao-transtorno-depressivo-maior-pt/ 2026-09-01T17:51:09+00:00 https://pt.psychopharmacologyinstitute.com/section/a-depressao-atipica-e-um-subtipo-clinico-distinto-pt/ 2026-09-01T17:51:14+00:00 https://pt.psychopharmacologyinstitute.com/section/catatonia-os-antipsicoticos-podem-prevenir-recaidas-pt/ 2026-09-01T17:51:22+00:00 https://pt.psychopharmacologyinstitute.com/section/qual-antipsicotico-adjuvante-e-melhor-para-a-depressao-maior-pt/ 2026-09-01T17:51:27+00:00 https://pt.psychopharmacologyinstitute.com/section/esquizofrenia-aguda-quais-antipsicoticos-sao-mais-eficazes-e-toleraveis-pt/ 2026-09-01T17:51:31+00:00 https://pt.psychopharmacologyinstitute.com/section/qual-e-o-efeito-dos-agonistas-do-receptor-glp-1-sobre-a-ansiedade-pt/ 2026-09-01T17:51:35+00:00 https://pt.psychopharmacologyinstitute.com/section/quais-tratamentos-realmente-ajudam-os-pacientes-a-parar-de-vaporizar-pt/ 2026-09-01T17:51:39+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-a-classificacao-de-evidencias-e-as-linhas-de-tratamento-do-canmat-para-depressao-pt/ 2026-09-01T17:52:10+00:00 https://pt.psychopharmacologyinstitute.com/section/tomada-de-decisao-compartilhada-no-tratamento-da-depressao-pt/ 2026-09-01T17:52:14+00:00 https://pt.psychopharmacologyinstitute.com/section/selecao-do-tratamento-inicial-para-depressao-pt/ 2026-09-01T17:52:18+00:00 https://pt.psychopharmacologyinstitute.com/section/medicina-complementar-e-alternativa-para-depressao-recomendacoes-da-canmat-pt/ 2026-09-01T17:52:22+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-de-manutencao-para-prevencao-da-depressao-pt/ 2026-09-01T17:52:26+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-da-depressao-de-dificil-tratamento-pt/ 2026-09-01T17:52:30+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-farmacologico-da-depressao-de-dificil-tratamento-opcoes-de-primeira-segunda-e-terceira-linha-pt/ 2026-09-01T17:52:33+00:00 https://pt.psychopharmacologyinstitute.com/section/estrategias-de-neuroestimulacao-para-o-manejo-da-depressao-de-dificil-tratamento-pt/ 2026-09-01T17:52:37+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-colaborando-com-os-pacientes-para-otimizar-o-tratamento-pt/ 2026-09-01T17:52:41+00:00 https://pt.psychopharmacologyinstitute.com/section/diretrizes-canmat-para-depressao-principais-conclusoes-pt/ 2026-09-01T17:52:45+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-a-dor-na-osteoartrite-e-na-fibromialgia/ 2026-09-01T17:52:52+00:00 https://pt.psychopharmacologyinstitute.com/section/caracterizacao-mecanicista-da-dor/ 2026-09-01T17:52:56+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-da-fibromialgia-2/ 2026-09-01T17:53:00+00:00 https://pt.psychopharmacologyinstitute.com/section/dor-centralizada-em-condicoes-de-dor-cronica/ 2026-09-01T17:53:05+00:00 https://pt.psychopharmacologyinstitute.com/section/fisiopatologia-e-neuroimagem-de-estados-de-dor-centralizada/ 2026-09-01T17:53:09+00:00 https://pt.psychopharmacologyinstitute.com/section/terapias-farmacologicas-para-fibromialgia/ 2026-09-01T17:53:13+00:00 https://pt.psychopharmacologyinstitute.com/section/fibromialgia-e-cannabis-medicinal/ 2026-09-01T17:53:17+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-de-dor-adaptados-aos-mecanismos-subjacentes/ 2026-09-01T17:53:21+00:00 https://pt.psychopharmacologyinstitute.com/section/terapias-nao-farmacologicas-para-fibromialgia/ 2026-09-01T17:53:25+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-8/ 2026-09-01T17:53:28+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-e-diagnostico-do-toc-resistente-ao-tratamento-pt/ 2026-09-01T17:53:36+00:00 https://pt.psychopharmacologyinstitute.com/section/visao-geral-das-estrategias-de-tratamento-do-toc-pt/ 2026-09-01T17:53:40+00:00 https://pt.psychopharmacologyinstitute.com/section/dosagem-de-ssri-no-toc-alem-das-diretrizes-da-fda-pt/ 2026-09-01T17:53:44+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-do-toc-alem-dos-tratamentos-de-primeira-linha-pt/ 2026-09-01T17:53:47+00:00 https://pt.psychopharmacologyinstitute.com/section/visao-geral-das-estrategias-de-potencializacao-no-toc-pt/ 2026-09-01T17:53:51+00:00 https://pt.psychopharmacologyinstitute.com/section/potencializacao-glutamatergica-no-toc-memantina-riluzol-lamotrigina-e-outros-agentes-pt/ 2026-09-01T17:53:55+00:00 https://pt.psychopharmacologyinstitute.com/section/antipsicoticos-de-segunda-geracao-para-potenciacao-no-toc-agentes-de-terceira-linha-pt/ 2026-09-01T17:53:59+00:00 https://pt.psychopharmacologyinstitute.com/section/outros-potenciadores-no-toc-buspirona-ondansetrona-e-opcoes-emergentes-pt/ 2026-09-01T17:54:02+00:00 https://pt.psychopharmacologyinstitute.com/section/neuroestimulacao-para-toc-tms-e-dbs-pt/ 2026-09-01T17:54:06+00:00 https://pt.psychopharmacologyinstitute.com/section/cirurgia-ablativa-para-toc-pt/ 2026-09-01T17:54:10+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-otimizacao-do-ssri-antes-da-estrategia-de-augmentacao-pt/ 2026-09-01T17:54:15+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-pt/ 2026-09-01T17:54:18+00:00 https://pt.psychopharmacologyinstitute.com/section/um-caso-clinico-criterios-do-dsm-5-epidemiologia-e-curso-dos-transtornos-de-tique-2/ 2026-09-01T17:54:26+00:00 https://pt.psychopharmacologyinstitute.com/section/compreensao-dos-transtornos-de-tique/ 2026-09-01T17:54:30+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-e-triagem-de-sintomas-de-tique-2/ 2026-09-01T17:54:34+00:00 https://pt.psychopharmacologyinstitute.com/section/diagnostico-diferencial-para-transtornos-de-tique/ 2026-09-01T17:54:38+00:00 https://pt.psychopharmacologyinstitute.com/section/transtornos-de-tique-e-comorbidades-psiquiatricas/ 2026-09-01T17:54:41+00:00 https://pt.psychopharmacologyinstitute.com/section/visao-geral-do-tratamento-para-transtornos-de-tique-2/ 2026-09-01T17:54:45+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-farmacologicos-primarios-para-tiques/ 2026-09-01T17:54:49+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-farmacologicos-secundarios/ 2026-09-01T17:54:53+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamento-farmacologico-terciario-para-tiques-2/ 2026-09-01T17:54:56+00:00 https://pt.psychopharmacologyinstitute.com/section/otimizacao-do-tratamento-para-transtornos-de-tique/ 2026-09-01T17:55:00+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-alternativos-e-experimentais-para-transtornos-de-tiques/ 2026-09-01T17:55:03+00:00 https://pt.psychopharmacologyinstitute.com/section/solucao-do-caso-clinico-e-dicas-para-medicos-que-tratam-de-transtornos-de-tique/ 2026-09-01T17:55:07+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-3/ 2026-09-01T17:55:11+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-a-menopausa-definicoes-clinicas-e-visao-geral-dos-sintomas-pt/ 2026-09-01T17:55:19+00:00 https://pt.psychopharmacologyinstitute.com/section/depressao-perimenopausica-apresentacao-clinica-e-mecanismos-neurobiologicos-pt/ 2026-09-01T17:55:23+00:00 https://pt.psychopharmacologyinstitute.com/section/identificacao-de-fatores-de-risco-para-depressao-perimenopausal-pt/ 2026-09-01T17:55:27+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-para-depressao-perimenopausal-pt/ 2026-09-01T17:55:30+00:00 https://pt.psychopharmacologyinstitute.com/section/terapia-hormonal-da-menopausa-thm-para-depressao-perimenopausica-pt/ 2026-09-01T17:55:34+00:00 https://pt.psychopharmacologyinstitute.com/section/manejo-dos-sintomas-vasomotores-svms-da-menopausa-evidencias-para-ssri-snri-e-tcc-pt/ 2026-09-01T17:55:38+00:00 https://pt.psychopharmacologyinstitute.com/section/ansiedade-perimenopausal-diferenciando-ondas-de-calor-de-ataques-de-panico-e-o-papel-da-alopregnanolona-pt/ 2026-09-01T17:55:42+00:00 https://pt.psychopharmacologyinstitute.com/section/ansiedade-perimenopausica-manejo-farmacologico-pt/ 2026-09-01T17:55:46+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-de-apoio-a-pratica-clinica-pt/ 2026-09-01T17:55:49+00:00 https://pt.psychopharmacologyinstitute.com/section/introducao-aos-disturbios-do-movimento-induzidos-por-medicamentos-pt/ 2026-09-01T17:55:57+00:00 https://pt.psychopharmacologyinstitute.com/section/acatisia-como-diagnosticar-e-manejar-pt/ 2026-09-01T17:56:01+00:00 https://pt.psychopharmacologyinstitute.com/section/sintomas-extrapiramidais-dicas-de-avaliacao-pt/ 2026-09-01T17:56:04+00:00 https://pt.psychopharmacologyinstitute.com/section/tremores-induzidos-por-psicofarmacos-diagnostico-e-manejo-pt/ 2026-09-01T17:56:08+00:00 https://pt.psychopharmacologyinstitute.com/section/sintomas-extrapiramidais-fatores-de-risco-relacionados-a-medicamentos-e-pacientes-pt/ 2026-09-01T17:56:13+00:00 https://pt.psychopharmacologyinstitute.com/section/sintomas-extrapiramidais-estrategias-de-manejo-pt/ 2026-09-01T17:56:17+00:00 https://pt.psychopharmacologyinstitute.com/section/discinesia-tardia-caracteristicas-clinicas-epidemiologia-e-mecanismos-pt/ 2026-09-01T17:56:21+00:00 https://pt.psychopharmacologyinstitute.com/section/discinesia-tardia-hierarquia-de-tratamento-pt/ 2026-09-01T17:56:25+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-os-efeitos-colaterais-neurocognitivos-dos-medicamentos-psicotropicos-pt/ 2026-09-01T17:56:28+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9710-pt/ 2026-09-01T17:56:32+00:00 https://pt.psychopharmacologyinstitute.com/section/controle-do-transtorno-bipolar-na-gravidez-dilemas-do-tratamento-2/ 2026-09-01T17:56:39+00:00 https://pt.psychopharmacologyinstitute.com/section/impacto-da-interrupcao-dos-estabilizadores-de-humor-na-gravidez/ 2026-09-01T17:56:43+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-do-uso-de-litio-na-gravidez-2/ 2026-09-01T17:56:47+00:00 https://pt.psychopharmacologyinstitute.com/section/transtorno-bipolar-durante-a-gravidez-controle-do-litio-2/ 2026-09-01T17:56:50+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-do-uso-do-valproato-na-gravidez/ 2026-09-01T17:56:54+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-do-uso-de-carbamazepina-e-lamotrigina-na-gravidez/ 2026-09-01T17:56:58+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-sobre-a-funcao-cognitiva-e-defeitos-do-tubo-neural-associados-a-exposicao-fetal-a-aeds/ 2026-09-01T17:57:01+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-do-uso-de-antipsicoticos-durante-a-gravidez/ 2026-09-01T17:57:05+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-do-uso-de-gabapentina-e-topiramato-na-gravidez/ 2026-09-01T17:57:08+00:00 https://pt.psychopharmacologyinstitute.com/section/principios-orientadores-para-o-tratamento-do-transtorno-bipolar-durante-a-gravidez-2/ 2026-09-01T17:57:12+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-uma-mulher-com-transtorno-bipolar-que-deseja-engravidar-2/ 2026-09-01T17:57:16+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-11/ 2026-09-01T17:57:19+00:00 https://pt.psychopharmacologyinstitute.com/section/o-papel-dos-antipsicoticos-de-acao-prolongada-injetaveis-no-tratamento-da-esquizofrenia-pt/ 2026-09-01T17:57:27+00:00 https://pt.psychopharmacologyinstitute.com/section/compreendendo-quando-prescrever-antipsicoticos-de-acao-prolongada-lais-pt/ 2026-09-01T17:57:32+00:00 https://pt.psychopharmacologyinstitute.com/section/por-que-escolher-lais-beneficios-na-esquizofrenia-pt/ 2026-09-01T17:57:36+00:00 https://pt.psychopharmacologyinstitute.com/section/equilibrando-riscos-desafios-do-tratamento-com-lai-pt/ 2026-09-01T17:57:40+00:00 https://pt.psychopharmacologyinstitute.com/section/orientando-a-conversa-como-discutir-os-lais-com-os-pacientes-pt/ 2026-09-01T17:57:44+00:00 https://pt.psychopharmacologyinstitute.com/section/ald-na-pratica-haloperidol-e-flufenazina-pt/ 2026-09-01T17:57:48+00:00 https://pt.psychopharmacologyinstitute.com/section/ald-na-pratica-aripiprazol-e-olanzapina-pt/ 2026-09-01T17:57:51+00:00 https://pt.psychopharmacologyinstitute.com/section/lais-na-pratica-paliperidona-risperidona-pt/ 2026-09-01T17:57:55+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-pt/ 2026-09-01T17:57:58+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-9010-pt/ 2026-09-01T17:58:02+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-cardiovasculares-dos-psicofarmacos-pressao-arterial-frequencia-cardiaca-e-risco-de-sangramento-pt/ 2026-09-08T16:31:00+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-cardiovasculares-dos-estimulantes-e-dos-medicamentos-nao-estimulantes-para-tdah-pt/ 2026-09-08T16:31:27+00:00 https://pt.psychopharmacologyinstitute.com/section/prolongamento-do-qt-com-antipsicoticos-estratificacao-de-risco-e-monitoramento-do-ecg-pt/ 2026-09-08T16:31:57+00:00 https://pt.psychopharmacologyinstitute.com/section/haloperidol-iv-e-torsades-de-pointes-separando-o-mito-da-evidencia-pt/ 2026-09-08T16:32:40+00:00 https://pt.psychopharmacologyinstitute.com/section/miocardite-e-cardiomiopatia-induzidas-por-clozapina-reconhecimento-e-monitoramento-pt/ 2026-09-08T16:33:03+00:00 https://pt.psychopharmacologyinstitute.com/section/sete-equivocos-sobre-o-qtc-e-os-medicamentos-psiquiatricos-pt/ 2026-09-08T16:35:13+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-chave-11511-pt/ 2026-09-08T16:36:13+00:00 https://pt.psychopharmacologyinstitute.com/section/casos-clinicos/ 2026-09-08T16:51:28+00:00 https://pt.psychopharmacologyinstitute.com/section/prolongamento-do-qt-com-antidepressivos-uma-classificacao-de-risco-pt/ 2026-09-08T17:08:34+00:00 https://pt.psychopharmacologyinstitute.com/section/efeitos-cardiacos-do-litio-da-lamotrigina-e-de-outros-estabilizadores-do-humor-pt/ 2026-09-08T17:09:17+00:00 https://pt.psychopharmacologyinstitute.com/section/prolongamento-do-intervalo-qt-com-metadona-donepezila-e-ibogaina-pt/ 2026-09-08T17:09:43+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-agitacao-e-qtc-prolongado-em-paciente-cardiaco-de-alto-risco-pt/ 2026-09-08T17:10:38+00:00 https://pt.psychopharmacologyinstitute.com/section/psicose-em-mulheres-o-status-hormonal-deve-mudar-a-sua-prescricao-pt/ 2026-09-08T18:30:32+00:00 https://pt.psychopharmacologyinstitute.com/section/esquizofrenia-o-semaglutida-supera-o-liraglutida-no-controle-do-ganho-de-peso-induzido-por-antipsicoticos-pt/ 2026-09-08T18:30:37+00:00 https://pt.psychopharmacologyinstitute.com/section/manutencao-do-transtorno-bipolar-classificando-os-farmacos-por-efetividade-no-mundo-real-pt/ 2026-09-08T18:30:43+00:00 https://pt.psychopharmacologyinstitute.com/section/o-carbonato-de-litio-em-dose-baixa-desacelera-o-declinio-cognitivo-no-comprometimento-cognitivo-leve-pt/ 2026-09-08T18:30:48+00:00 https://pt.psychopharmacologyinstitute.com/section/terapia-cetogenica-em-transtornos-mentais-graves-consenso-de-especialistas-pt/ 2026-09-08T18:30:53+00:00 https://pt.psychopharmacologyinstitute.com/section/antidepressivos-na-gravidez-aumentam-o-risco-de-autismo-e-tdah-pt/ 2026-09-09T02:08:51+00:00 https://pt.psychopharmacologyinstitute.com/section/os-ssris-aumentam-o-risco-de-arritmia-e-morte-subita-quando-associados-a-antipsicoticos-pt/ 2026-09-09T02:08:56+00:00 https://pt.psychopharmacologyinstitute.com/section/reintroducao-de-clozapina-apos-neutropenia-contraindicacao-absoluta-ou-relativa-pt/ 2026-09-09T02:09:00+00:00 https://pt.psychopharmacologyinstitute.com/section/devemos-renomear-a-esquizofrenia-pt/ 2026-09-09T02:09:05+00:00 https://pt.psychopharmacologyinstitute.com/section/ashwagandha-associada-a-melatonina-para-o-sono-melhor-do-que-cada-uma-isoladamente-pt/ 2026-09-09T02:09:09+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-os-conceitos-basicos-do-emt/ 2026-09-09T04:15:44+00:00 https://pt.psychopharmacologyinstitute.com/section/dispositivos-e-bobinas-de-emt-aprovados-pela-fda/ 2026-09-09T04:16:04+00:00 https://pt.psychopharmacologyinstitute.com/section/a-ciencia-por-tras-da-emt-circuitos-cerebrais/ 2026-09-09T04:16:23+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-dos-possiveis-efeitos-colaterais-da-emt/ 2026-09-09T04:16:41+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-evidencias-da-emt-para-depressao/ 2026-09-09T04:17:00+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-as-evidencias-da-emt-para-o-toc/ 2026-09-09T04:17:24+00:00 https://pt.psychopharmacologyinstitute.com/section/inovacoes-recentes-na-pesquisa-e-na-pratica-da-emt/ 2026-09-09T04:17:49+00:00 https://pt.psychopharmacologyinstitute.com/section/otimizacao-da-selecao-de-pacientes-para-tratamento-com-emt/ 2026-09-09T04:18:09+00:00 https://pt.psychopharmacologyinstitute.com/section/explorando-outros-usos-da-emt/ 2026-09-09T04:18:30+00:00 https://pt.psychopharmacologyinstitute.com/section/caso-clinico-2/ 2026-09-09T04:18:48+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-16/ 2026-09-09T04:19:08+00:00 https://pt.psychopharmacologyinstitute.com/section/benzodiazepinicos-tracando-sua-historia/ 2026-09-09T04:19:48+00:00 https://pt.psychopharmacologyinstitute.com/section/benzodiazepinicos-neurofarmacologia-e-desenvolvimento-de-tolerancia/ 2026-09-09T04:20:08+00:00 https://pt.psychopharmacologyinstitute.com/section/uso-adequado-de-benzodiazepinicos-indicacoes-e-selecao-ideal/ 2026-09-09T04:20:26+00:00 https://pt.psychopharmacologyinstitute.com/section/riscos-dos-benzodiazepinicos-contraindicacoes-e-efeitos-colaterais/ 2026-09-09T04:20:47+00:00 https://pt.psychopharmacologyinstitute.com/section/entendendo-os-principais-riscos-do-uso-de-benzodiazepinicos/ 2026-09-09T04:21:07+00:00 https://pt.psychopharmacologyinstitute.com/section/a-crise-dos-benzodiazepinicos-prescricao-excessiva-dependencia-fisica-uso-indevido-e-vicio/ 2026-09-09T04:21:27+00:00 https://pt.psychopharmacologyinstitute.com/section/transtorno-por-uso-de-benzodiazepinicos/ 2026-09-09T04:21:46+00:00 https://pt.psychopharmacologyinstitute.com/section/consequencias-do-uso-de-benzodiazepinicos-em-populacoes-de-alto-risco/ 2026-09-09T04:22:05+00:00 https://pt.psychopharmacologyinstitute.com/section/consequencias-do-uso-de-benzodiazepinicos-na-gravidez-na-amamentacao-e-na-adolescencia/ 2026-09-09T04:22:29+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-clinica-estrategias-para-o-uso-mais-seguro-de-benzodiazepinicos/ 2026-09-09T04:22:50+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-17/ 2026-09-09T04:23:09+00:00 https://pt.psychopharmacologyinstitute.com/section/tdah-adulto-entendendo-a-prevalencia-a-persistencia-e-as-comorbidades/ 2026-09-09T04:23:51+00:00 https://pt.psychopharmacologyinstitute.com/section/vinheta-de-caso-de-tdah-em-adultos-sr-jones/ 2026-09-09T04:24:10+00:00 https://pt.psychopharmacologyinstitute.com/section/triagem-para-tdah-o-que-os-medicos-devem-procurar/ 2026-09-09T04:24:29+00:00 https://pt.psychopharmacologyinstitute.com/section/avaliacao-do-tdah-em-adultos-entrevista-clinica-e-escalas-de-avaliacao/ 2026-09-09T04:24:46+00:00 https://pt.psychopharmacologyinstitute.com/section/algoritmo-de-tratamento-para-tdah-em-adultos/ 2026-09-09T04:25:04+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-farmacologicos-para-o-tdah-adulto-foco-nos-estimulantes/ 2026-09-09T04:25:24+00:00 https://pt.psychopharmacologyinstitute.com/section/estimulantes-consideracoes-clinicas-prevencao-de-abuso-e-sinais-de-alerta/ 2026-09-09T04:25:45+00:00 https://pt.psychopharmacologyinstitute.com/section/tratamentos-nao-estimulantes-para-tdah-em-adultos/ 2026-09-09T04:26:04+00:00 https://pt.psychopharmacologyinstitute.com/section/psicoterapia-abordagens-psicossociais-e-neurofeedback-para-tdah-adulto/ 2026-09-09T04:26:23+00:00 https://pt.psychopharmacologyinstitute.com/section/mensagens-para-levar-para-casa-18/ 2026-09-09T04:26:43+00:00